Nothing Special   »   [go: up one dir, main page]

ATE372379T1 - Hybride and einzelkettige meganukleasen und deren anwendungen - Google Patents

Hybride and einzelkettige meganukleasen und deren anwendungen

Info

Publication number
ATE372379T1
ATE372379T1 AT03744485T AT03744485T ATE372379T1 AT E372379 T1 ATE372379 T1 AT E372379T1 AT 03744485 T AT03744485 T AT 03744485T AT 03744485 T AT03744485 T AT 03744485T AT E372379 T1 ATE372379 T1 AT E372379T1
Authority
AT
Austria
Prior art keywords
rare
hybrid
polynucleotide sequences
cutting endonucleases
cutting
Prior art date
Application number
AT03744485T
Other languages
English (en)
Inventor
Sylvain Arnould
Patrick Chames
Andre Choulika
Jean-Charles Epinat
Emmanuel Lacroix
Original Assignee
Cellectis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28041871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE372379(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cellectis filed Critical Cellectis
Application granted granted Critical
Publication of ATE372379T1 publication Critical patent/ATE372379T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Detergent Compositions (AREA)
AT03744485T 2002-03-15 2003-03-14 Hybride and einzelkettige meganukleasen und deren anwendungen ATE372379T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36411302P 2002-03-15 2002-03-15

Publications (1)

Publication Number Publication Date
ATE372379T1 true ATE372379T1 (de) 2007-09-15

Family

ID=28041871

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03744485T ATE372379T1 (de) 2002-03-15 2003-03-14 Hybride and einzelkettige meganukleasen und deren anwendungen

Country Status (10)

Country Link
US (2) US8206965B2 (de)
EP (1) EP1485475B2 (de)
JP (3) JP2005520519A (de)
AT (1) ATE372379T1 (de)
AU (1) AU2003215869B2 (de)
CA (1) CA2479153C (de)
DE (1) DE60316124T3 (de)
DK (1) DK1485475T3 (de)
ES (1) ES2292994T3 (de)
WO (1) WO2003078619A1 (de)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE372379T1 (de) * 2002-03-15 2007-09-15 Cellectis Hybride and einzelkettige meganukleasen und deren anwendungen
WO2009095742A1 (en) * 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
US20100151556A1 (en) * 2002-03-15 2010-06-17 Cellectis Hybrid and single chain meganucleases and use thereof
CA2514417A1 (en) 2003-01-28 2004-08-12 Cellectis Custom-made meganuclease and use thereof
US20070134796A1 (en) * 2005-07-26 2007-06-14 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
EP1591521A1 (de) 2004-04-30 2005-11-02 Cellectis I-Dmo I -Derivate mit erhöhter Aktivität bei 37 Grad C und deren Verwendung
WO2007034262A1 (en) * 2005-09-19 2007-03-29 Cellectis Heterodimeric meganucleases and use thereof
US7897372B2 (en) * 2005-03-15 2011-03-01 Cellectis I-CreI meganuclease variants with modified specificity, method of preparation and uses thereof
ATE549401T1 (de) 2005-10-18 2012-03-15 Prec Biosciences Rational konstruierte meganukleasen mit veränderter sequenzspezifität und dna- bindungsaffinität
WO2007049095A1 (en) 2005-10-25 2007-05-03 Cellectis Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof
WO2007060495A1 (en) 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
WO2008010009A1 (en) * 2006-07-18 2008-01-24 Cellectis Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof
WO2008093152A1 (en) * 2007-02-01 2008-08-07 Cellectis Obligate heterodimer meganucleases and uses thereof
DK2336329T3 (da) 2007-06-01 2013-01-07 Omt Inc Sammensætninger og fremgangsmåder til hæmning af endogene immunglobulingener og til produktion af transgene, humane, idiotypiske antistoffer
WO2008149176A1 (en) * 2007-06-06 2008-12-11 Cellectis Meganuclease variants cleaving a dna target sequence from the mouse rosa26 locus and uses thereof
AU2008263502A1 (en) 2007-06-06 2008-12-18 Cellectis Method for enhancing the cleavage activity of I-Crei derived meganucleases
EP2568048A1 (de) 2007-06-29 2013-03-13 Pioneer Hi-Bred International, Inc. Verfahren zur Veränderung des Genoms einer Zelle von Einkeimblättrigen
WO2009013559A1 (en) 2007-07-23 2009-01-29 Cellectis Meganuclease variants cleaving a dna target sequence from the human hemoglobin beta gene and uses thereof
WO2009019528A1 (en) * 2007-08-03 2009-02-12 Cellectis Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof
AU2008305567B2 (en) * 2007-09-27 2014-04-10 Sangamo Therapeutics, Inc. Rapid in vivo identification of biologically active nucleases
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
US20110014616A1 (en) * 2009-06-30 2011-01-20 Sangamo Biosciences, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
AU2015201270B2 (en) * 2007-10-31 2017-01-19 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
JP5761996B2 (ja) * 2007-10-31 2015-08-12 プレシジョン バイオサイエンシズ，インク． 合理的に設計された、非パリンドローム認識配列を有する単鎖メガヌクレアーゼ
CA2703079A1 (en) * 2007-12-07 2009-06-18 Precision Biosciences, Inc. Rationally-designed meganucleases with recognition sequences found in dnase hypersensitive regions of the human genome
WO2009074842A1 (en) * 2007-12-13 2009-06-18 Cellectis Improved chimeric meganuclease enzymes and uses thereof
WO2009114321A2 (en) 2008-03-11 2009-09-17 Precision Biosciencs, Inc. Rationally-designed meganucleases for maize genome engineering
US20100071083A1 (en) * 2008-03-12 2010-03-18 Smith James J Temperature-dependent meganuclease activity
EP2279250A4 (de) * 2008-04-28 2011-10-12 Prec Biosciences Inc Fusionsmoleküle von dna-bindenden proteinen mit rationalem design und effektor-domänen
EP2313498B1 (de) 2008-07-14 2017-03-15 Precision Biosciences, Inc. Erkennungssequenzen für meganukleasen aus i-crei und ihre verwendung
WO2010026443A1 (en) * 2008-09-08 2010-03-11 Cellectis Meganuclease variants cleaving a dna target sequence from a glutamine synthetase gene and uses thereof
EP2180058A1 (de) 2008-10-23 2010-04-28 Cellectis Meganuklease-Rekombinationssystem
EP2208785A1 (de) 2009-01-15 2010-07-21 Newbiotechnic, S.A. Verfahren und Kits zum Erzeugen von miRNA- und smallRNA-Expressionsvektoren und ihre Anwendung zur Entwicklung von lentiviralen Expressionsbibliotheken
WO2010093966A2 (en) * 2009-02-12 2010-08-19 Fred Hutchinson Cancer Research Center Generation of a dna nicking enzyme that stimulates site-specific gene conversion from a homing endonuclease
EP2408921B1 (de) 2009-03-20 2017-04-19 Sangamo BioSciences, Inc. Modifikation von cxcr4 mit manipulierten zink-fingerproteinen
WO2010122367A2 (en) * 2009-04-21 2010-10-28 Cellectis Meganuclease variants cleaving the genomic insertion of a virus and uses thereof
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
WO2010136981A2 (en) 2009-05-26 2010-12-02 Cellectis Meganuclease variants cleaving the genome of a pathogenic non-integrating virus and uses thereof
WO2011007193A1 (en) 2009-07-17 2011-01-20 Cellectis Viral vectors encoding a dna repair matrix and containing a virion-associated site specific meganuclease for gene targeting
US9234016B2 (en) 2009-07-28 2016-01-12 Sangamo Biosciences, Inc. Engineered zinc finger proteins for treating trinucleotide repeat disorders
CN102612565B (zh) 2009-08-11 2016-04-06 桑格摩生物科学股份有限公司 靶向修饰的纯合生物体
WO2011021062A1 (en) 2009-08-21 2011-02-24 Cellectis Meganuclease variants cleaving a dna target sequence from the human lysosomal acid alpha-glucosidase gene and uses thereof
EP2480659A2 (de) 2009-09-24 2012-08-01 Cellectis Meganukleasereagenzien zur verwendung bei der behandlung genetischer, durch rasterschub-/nonsense-mutationen hervorgerufener erkrankungen
US10316304B2 (en) 2009-11-27 2019-06-11 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
DE112010004584T5 (de) 2009-11-27 2012-11-29 Basf Plant Science Company Gmbh Chimäre Endonukleasen und Anwendungen davon
EP2529017A2 (de) 2009-12-30 2012-12-05 Pioneer Hi-Bred International, Inc. Verfahren und zusammensetzungen für gezielte polynukleotidmodifikation
EP2531609A1 (de) * 2010-02-02 2012-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur diagnose und therapie von retinitis pigmentosa
WO2011101696A1 (en) 2010-02-18 2011-08-25 Cellectis Improved meganuclease recombination system
WO2011104382A1 (en) 2010-02-26 2011-09-01 Cellectis Use of endonucleases for inserting transgenes into safe harbor loci
EP2550358A1 (de) 2010-03-22 2013-01-30 Philip Morris Products S.A. Modifizierung der enzymaktivität in pflanzen
CA2799095A1 (en) 2010-05-12 2011-11-17 Cellectis Meganuclease variants cleaving a dna target sequence from the dystrophin gene and uses thereof
EP2569435A1 (de) 2010-05-12 2013-03-20 Cellectis Eine dna-zielsequenz von einem rhodopsin-gen abspaltende meganukleasevarianten und ihre verwendung
JP6208580B2 (ja) 2010-05-17 2017-10-04 サンガモ セラピューティクス， インコーポレイテッド 新規のｄｎａ結合タンパク質及びその使用
EP2582845A2 (de) 2010-06-15 2013-04-24 Cellectis Verfahren zur verbesserung einer dna-spaltung durch für methylierung empfindliche endonuklease
WO2012004671A2 (en) 2010-07-07 2012-01-12 Cellectis Meganucleases variants cleaving a dna target sequence in the nanog gene and uses thereof
WO2012010976A2 (en) 2010-07-15 2012-01-26 Cellectis Meganuclease variants cleaving a dna target sequence in the tert gene and uses thereof
WO2012007848A2 (en) 2010-07-16 2012-01-19 Cellectis Meganuclease variants cleaving a dna target sequence in the was gene and uses thereof
AU2011287293B2 (en) 2010-08-02 2015-02-26 Cellectis S.A. Method for targeted genomic events in algae
CA2815512A1 (en) 2010-10-27 2012-05-03 Philippe Duchateau Method for increasing the efficiency of double-strand break-induced mutagenesis
US9044492B2 (en) 2011-02-04 2015-06-02 Cellectis Sa Method for modulating the efficiency of double-strand break-induced mutagenesis
WO2012129373A2 (en) 2011-03-23 2012-09-27 Pioneer Hi-Bred International, Inc. Methods for producing a complex transgenic trait locus
US9315788B2 (en) 2011-04-05 2016-04-19 Cellectis, S.A. Method for the generation of compact TALE-nucleases and uses thereof
WO2012138901A1 (en) 2011-04-05 2012-10-11 Cellectis Sa Method for enhancing rare-cutting endonuclease efficiency and uses thereof
BR112013025567B1 (pt) 2011-04-27 2021-09-21 Amyris, Inc Métodos para modificação genômica
WO2012158778A1 (en) 2011-05-16 2012-11-22 Cellectis S.A. Doubly secure transgenic algae or cyanobacteria strains to prevent their establishment and spread in natural ecosystems
US9758796B2 (en) 2011-06-10 2017-09-12 Basf Plant Science Company Gmbh Nuclease fusion protein and uses thereof
CA2844470A1 (en) 2011-06-21 2013-05-10 Pioneer Hi-Bred International, Inc. Methods and compositions for producing male sterile plants
WO2013009525A1 (en) 2011-07-08 2013-01-17 Cellectis S.A. Method for increasing the efficiency of double-strand break-induced mutagenssis
CA2844101A1 (en) 2011-08-03 2013-02-07 E. I. Du Pont De Nemours And Company Methods and compositions for targeted integration in a plant
AU2013225950B2 (en) 2012-02-29 2018-02-15 Sangamo Therapeutics, Inc. Methods and compositions for treating huntington's disease
CA2872096A1 (en) 2012-05-04 2013-11-07 E. I. Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
EP2877488B1 (de) 2012-07-24 2021-02-24 Cellectis Neue modulare basenspezifische nukleinsäurebindende domänen aus burkholderia-rhizoxinica-proteinen
HUE050797T2 (hu) 2012-10-10 2021-01-28 Sangamo Therapeutics Inc T-sejt módosító vegyületek és alkalmazásaik
WO2014076571A2 (en) 2012-11-16 2014-05-22 Cellectis Method for targeted modification of algae genomes
WO2014102688A1 (en) 2012-12-27 2014-07-03 Cellectis New design matrix for improvement of homology-directed gene targeting
KR102209979B1 (ko) 2013-02-20 2021-02-01 리제너론 파마슈티칼스 인코포레이티드 랫트의 유전자 변형
CA2905289C (en) 2013-03-12 2023-03-07 Pioneer Hi-Bred International, Inc. Methods for the identification of variant recognition sites for rare-cutting engineered double-strand-break-inducing agents and compositions and uses thereof
CN111978409B (zh) 2013-03-15 2024-01-26 因斯瑞拜奥有限公司 自组装合成蛋白
SI2986729T1 (sl) 2013-04-16 2019-02-28 Regeneron Pharmaceuticals, Inc. Ciljana sprememba genoma podgane
RU2693891C1 (ru) 2013-11-11 2019-07-05 Сангамо Байосайенсиз, Инк. Способы и композиции для лечения болезни хантингтона
CA2933433C (en) 2013-12-11 2020-11-17 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
RS58159B1 (sr) 2013-12-11 2019-03-29 Regeneron Pharma Postupci i kompozicije za ciljanu modifikaciju genoma
WO2015095804A1 (en) 2013-12-19 2015-06-25 Amyris, Inc. Methods for genomic integration
DK3083671T3 (da) 2013-12-20 2020-12-07 Hutchinson Fred Cancer Res Mærkede kimære effektormolekyler og receptorer deraf
CN106459894B (zh) 2014-03-18 2020-02-18 桑格摩生物科学股份有限公司 用于调控锌指蛋白表达的方法和组合物
SG10201913804WA (en) 2014-06-06 2020-03-30 Regeneron Pharma Methods and compositions for modifying a targeted locus
DK3155099T3 (en) 2014-06-23 2018-05-07 Regeneron Pharma NUCLEASE MEDIATED DNA COLLECTION
KR102386101B1 (ko) 2014-06-26 2022-04-14 리제너론 파마슈티칼스 인코포레이티드 표적화된 유전자 변형을 위한 방법 및 그 조성물, 및 사용 방법
SG11201702309RA (en) 2014-10-15 2017-04-27 Regeneron Pharma Methods and compositions for generating or maintaining pluripotent cells
ES2760508T3 (es) 2014-12-19 2020-05-14 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida a través de la transformación múltiple en una sola etapa
ES2959608T3 (es) 2015-04-03 2024-02-27 Dana Farber Cancer Inst Inc Composición y métodos de edición del genoma de células B
US11827904B2 (en) 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
US11352631B2 (en) 2015-12-18 2022-06-07 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
CN117137947A (zh) 2015-12-18 2023-12-01 桑格摩生物治疗股份有限公司 Mhc细胞受体的靶向破坏
WO2017201311A2 (en) 2016-05-18 2017-11-23 Amyris, Inc. Compositions and methods for genomic integration of nucleic acids into exogenous landing pads
RU2721125C1 (ru) 2016-07-29 2020-05-18 Регенерон Фармасьютикалз, Инк. Мыши, содержащие мутации, вследствие которых экспрессируется укороченный на с-конце фибриллин-1
IL300783A (en) 2016-08-24 2023-04-01 Sangamo Therapeutics Inc Engineered target-specific zinc-finger nucleases
MX2019003176A (es) 2016-09-23 2019-07-04 Hutchinson Fred Cancer Res Receptores de linfocitos t (tcr) especificos del antigeno menor de histocompatibilidad (h) ah-1 y sus usos.
KR20190104400A (ko) 2017-01-19 2019-09-09 오픈 모노클로날 테크놀로지, 인코포레이티드 다중 중쇄 면역글로불린 유전자좌를 갖는 트랜스제닉 설치류 기원의 인간 항체
CN110582299A (zh) 2017-03-15 2019-12-17 弗雷德哈钦森癌症研究中心 高亲和力mage-a1特异性tcr及其用途
WO2018200943A1 (en) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
US11655275B2 (en) 2017-05-03 2023-05-23 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
CA3064000A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
CN111511199A (zh) 2017-08-29 2020-08-07 科沃施种子欧洲股份两合公司 改良蓝色糊粉及其他分离系统
EP3678690A1 (de) 2017-09-06 2020-07-15 Fred Hutchinson Cancer Research Center Verfahren zur verbesserung einer adoptiven zelltherapie
CN111051349A (zh) 2017-09-06 2020-04-21 弗雷德哈钦森癌症研究中心 Strep-tag特异性嵌合受体及其用途
SG11202000771UA (en) 2017-09-29 2020-04-29 Regeneron Pharma Non-human animals comprising a humanized ttr locus and methods of use
EP3697435A1 (de) 2017-10-20 2020-08-26 Fred Hutchinson Cancer Research Center Zusammensetzungen und verfahren zur immuntherapie gegen tigit und/oder cd112r oder mit cd226-überexpression
US20220267403A1 (en) 2017-12-01 2022-08-25 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
WO2019140278A1 (en) 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunotherapy targeting core binding factor antigens
JP2021514631A (ja) 2018-02-26 2021-06-17 フレッド ハッチンソン キャンサー リサーチ センター 細胞免疫療法のための組成物および方法
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
AU2019324162A1 (en) 2018-08-22 2021-03-04 Fred Hutchinson Cancer Center Immunotherapy targeting KRAS or Her2 antigens
BR112021003830A2 (pt) 2018-08-28 2021-07-20 Fred Hutchinson Cancer Research Center métodos e composições para terapia celular t adotiva incorporando sinalização notch induzida
CN113015741A (zh) 2018-09-18 2021-06-22 桑格摩生物治疗股份有限公司 程序性细胞死亡1(pd1)特异性核酸酶
US20240165232A1 (en) 2018-09-24 2024-05-23 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
US20220009992A1 (en) 2018-11-09 2022-01-13 Fred Hutchinson Cancer Research Center T cell receptors specific for mesothelin and their use in immunotherapy
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
CN113423831B (zh) 2018-12-20 2023-03-10 瑞泽恩制药公司 核酸酶介导的重复扩增
PT3908568T (pt) 2019-01-11 2024-09-30 Acuitas Therapeutics Inc Lípidos para a administração de agentes ativos por nanopartículas lipídicas
KR20210130189A (ko) 2019-02-20 2021-10-29 프레드 헛친슨 켄서 리서치 센터 Ras 신항원에 특이적인 결합 단백질 및 이의 용도
SG11202109745PA (en) 2019-03-11 2021-10-28 Hutchinson Fred Cancer Res High avidity wt1 t cell receptors and uses thereof
WO2020206134A1 (en) 2019-04-04 2020-10-08 Regeneron Pharmaceuticals, Inc. Methods for scarless introduction of targeted modifications into targeting vectors
CN117178959A (zh) 2019-04-04 2023-12-08 瑞泽恩制药公司 包括人源化凝血因子12基因座的非人动物
JP2022534867A (ja) 2019-06-04 2022-08-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ベータスリップ変異を有するヒト化ｔｔｒ遺伝子座を含む非ヒト動物と使用方法
CN113939595A (zh) 2019-06-07 2022-01-14 瑞泽恩制药公司 包括人源化白蛋白基因座的非人动物
KR20220050176A (ko) 2019-08-20 2022-04-22 프레드 헛친슨 켄서 리서치 센터 Wt-1에 특이적인 t-세포 면역요법
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
AU2021308681A1 (en) 2020-07-16 2023-03-09 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
WO2022046760A2 (en) 2020-08-25 2022-03-03 Kite Pharma, Inc. T cells with improved functionality
WO2022066965A2 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting sox2 antigens
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
WO2022076353A1 (en) 2020-10-06 2022-04-14 Fred Hutchinson Cancer Research Center Compositions and methods for treating mage-a1-expressing disease
CA3201767A1 (en) 2020-12-14 2022-06-23 Thomas M. Schmitt Compositions and methods for cellular immunotherapy
US20240247285A1 (en) 2021-05-10 2024-07-25 Sqz Biotechnologies Company Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
WO2022256437A1 (en) 2021-06-02 2022-12-08 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
TW202317602A (zh) 2021-07-15 2023-05-01 福瑞德哈金森腫瘤中心 嵌合多肽
EP4380967A1 (de) 2021-08-04 2024-06-12 The Regents of the University of Colorado, a body corporate Lat-aktivierende chimäre antigenrezeptor-t-zellen und verfahren zur verwendung davon
IL311962A (en) 2021-10-14 2024-06-01 Lonza Sales Ag Producer cells are adapted to produce extracellular vesicles
WO2023081756A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
KR20240123832A (ko) 2021-12-16 2024-08-14 아퀴타스 테라퓨틱스 인크. 지질 나노입자 제형에 사용하기 위한 지질
KR20240128067A (ko) 2021-12-29 2024-08-23 브리스톨-마이어스 스큅 컴퍼니 랜딩 패드 세포주의 생성
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2023220603A1 (en) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2023225665A1 (en) 2022-05-19 2023-11-23 Lyell Immunopharma, Inc. Polynucleotides targeting nr4a3 and uses thereof
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5006333A (en) * 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
FR2646438B1 (fr) * 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US6063630A (en) * 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US20040019916A1 (en) * 1992-04-24 2004-01-29 Zarling David A. In vivo homologous sequence targeting in eukaryotic cells
US6395959B1 (en) * 1992-05-05 2002-05-28 Institut Pasteur Nucleotide sequence encoding the enzyme I SceI and the use thereof
US5792632A (en) * 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5474896A (en) * 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
AU6234594A (en) 1993-02-12 1994-08-29 Johns Hopkins University, The Functional domains in (flavobacterium okeanokoites) (foki) restriction endonuclease
US5801030A (en) * 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US5830729A (en) * 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
IL120241A0 (en) * 1997-02-17 1997-06-10 B G Negev Technologies And App DNA segments encoding a domain of ho-endonuclease
US6232112B1 (en) * 1997-11-24 2001-05-15 Flinders Technologies Pty Ltd Of Flinders University Reagents and methods for diversification of DNA
EP1147209A2 (de) 1999-02-03 2001-10-24 The Children's Medical Center Corporation Genreparatur durch induzierte doppelsträngige dna-schneidung an einer chromosomalen targetstelle
EP1151124A1 (de) 1999-02-03 2001-11-07 The Children's Medical Center Corporation Genreparatur durch in vivo excision von targeting dna
WO2002068471A2 (en) * 2000-12-21 2002-09-06 Bristol-Myers Squibb Company Nucleic acid molecules and polypeptides for a human cation channel polypeptide
DE10131786A1 (de) * 2001-07-04 2003-01-16 Sungene Gmbh & Co Kgaa Rekombinationssysteme und Verfahren zum Entfernen von Nukleinsäuresequenzen aus dem Genom eukaryotischer Organismen
AU2002353934A1 (en) * 2001-10-31 2003-05-12 Oxford Glycosciences (Uk) Ltd. Biomarkers of liver function
AU2002360986A1 (en) * 2001-12-20 2003-07-09 Sungene Gmbh And Co. Kgaa Methods for the transformation of vegetal plastids
WO2009095742A1 (en) † 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
ATE372379T1 (de) * 2002-03-15 2007-09-15 Cellectis Hybride and einzelkettige meganukleasen und deren anwendungen
CA2514417A1 (en) * 2003-01-28 2004-08-12 Cellectis Custom-made meganuclease and use thereof
US7888121B2 (en) * 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP1591521A1 (de) 2004-04-30 2005-11-02 Cellectis I-Dmo I -Derivate mit erhöhter Aktivität bei 37 Grad C und deren Verwendung
ATE549401T1 (de) † 2005-10-18 2012-03-15 Prec Biosciences Rational konstruierte meganukleasen mit veränderter sequenzspezifität und dna- bindungsaffinität
EP2568048A1 (de) † 2007-06-29 2013-03-13 Pioneer Hi-Bred International, Inc. Verfahren zur Veränderung des Genoms einer Zelle von Einkeimblättrigen
JP5761996B2 (ja) † 2007-10-31 2015-08-12 プレシジョン バイオサイエンシズ，インク． 合理的に設計された、非パリンドローム認識配列を有する単鎖メガヌクレアーゼ
WO2009074842A1 (en) † 2007-12-13 2009-06-18 Cellectis Improved chimeric meganuclease enzymes and uses thereof

Also Published As

Publication number Publication date
CA2479153C (en) 2015-06-02
US20060078552A1 (en) 2006-04-13
DE60316124T3 (de) 2018-03-22
CA2479153A1 (en) 2003-09-25
ES2292994T3 (es) 2008-03-16
EP1485475A1 (de) 2004-12-15
DE60316124T2 (de) 2008-06-05
JP2005520519A (ja) 2005-07-14
DK1485475T3 (da) 2008-01-21
EP1485475B2 (de) 2017-09-20
WO2003078619A1 (en) 2003-09-25
JP2010207234A (ja) 2010-09-24
EP1485475B1 (de) 2007-09-05
DE60316124D1 (de) 2007-10-18
AU2003215869A1 (en) 2003-09-29
US20040002092A1 (en) 2004-01-01
US8206965B2 (en) 2012-06-26
AU2003215869B2 (en) 2008-04-24
JP2011188867A (ja) 2011-09-29

Similar Documents

Publication Publication Date Title
ATE372379T1 (de) Hybride and einzelkettige meganukleasen und deren anwendungen
KR102212257B1 (ko) 드 노보 합성된 핵산 라이브러리
WO2004067736A3 (en) Custom-made meganuclease and use thereof
HRP20200523T1 (hr) Sastavljanje dnk posredovano nukleazom
ATE494370T1 (de) Vektoren auf transposonbasis und verfahren zur integration von nukleinsäuren
WO2018191715A3 (en) Polypeptides with type v crispr activity and uses thereof
EP4253551A3 (de) Neuartige, auf dna und rna gerichtete crispr enzyme und systeme
Jurkowska et al. Mechanisms and biological roles of DNA methyltransferases and DNA methylation: from past achievements to future challenges
CN109310784A (zh) 用于制备和使用指导核酸的方法和组合物
MXPA05001239A (es) Secuencias de acidos nucleicos de diacilglicerol aciltransferasa y productos asociados.
NO20084488L (no) Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
ATE536415T1 (de) Klonierung des cytochrome p450 gens von nicotiana
WO2006036739A3 (en) Gene silencing
DE10345772A1 (de) Verfahren zur Herstellung von 3-Methylamino-1-(thien-2-yl)-propan-1-ol
HUP0303517A2 (hu) Hímfertilitást közvetítő nukleotidszekvenciák és alkalmazásuk
EA201070229A1 (ru) Нуклеотидные последовательности msca1, влияющие на мужскую фертильность растений, и способ их применения
WO2003035842A3 (en) Hybridization control of sequence variation
HUP0101991A2 (hu) Peszticid toxinok és az ezeket kódoló nukleotid szekvenciák
BR0309766A (pt) Promotores usp semente especìficos para expressar genes em vegetais
Ranzau et al. Genome, epigenome, and transcriptome editing via chemical modification of nucleobases in living cells
SE9503117D0 (sv) Novel use of padlock probes
NO20005586L (no) Genomiske sekvenser oppströms for den kodende regionen til G- CSF genet for produksjon og levering av protein
GB2421950B (en) Method of mutagenesis
TW200602487A (en) Polypeptides having DNA polymerase activity
WO2003008572A8 (en) Methods of creating genetic diversity

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1485475

Country of ref document: EP